The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Atherosclerotic Disease in Marked Hyperalphalipoproteinemia: Combined Reduction of Cholesteryl Ester Transfer Protein and Hepatic Triglyceride Lipase
Open accessAbstract
Abstract Hyperalphalipoproteinemia (HALP) has been regarded as a beneficial state accompanied by a longevity syndrome. However, we reported the cases of markedly hyperalphalipoproteinemic subjects with juvenile corneal opacification. These patients had reduced postheparin hepatic triglyceride lipase (HTGL) activities, and one of them has recently been identified to be homozygous for a missense mutation in exon 15 (D442: G) in the cholesteryl ester transfer protein (CETP) gene. In the current study, to elucidate the clinical significance of and atherogenicity in marked HALP, we determined the incidence of atherosclerotic cardiovascular disease (ACD) in patients with marked HALP and characterized the lipoprotein abnormalities in those who had ACD, focusing especially on CETP and HTGL. The subjects were 201 patients (111 males and 90 females) with marked HALP (≥2.58 mmol/L [100 mg/dL]), 67% of whom were demonstrated to have the CETP gene mutations in the intron 14 splice donor site or in exon 15. Their mean age was 54±15 years. Plasma levels of total cholesterol, HDL cholesterol, and triglyceride in all subjects were 6.28±1.78, 3.15±0.90, and 1.08±0.53 mmol/L, respectively. Ten of the male patients (9.0%) and two of the female patients (2.2%) had apparent ACD such as myocardial infarction, angina pectoris, and peripheral vascular diseases. Ten patients with HALP who had ACD were identified to be heterozygotes for CETP deficiency. To further clarify the characteristics of marked HALP in patients with ACD, we compared the plasma lipids, lipoproteins, CETP, and HTGL activities between heterozygotes for CETP deficiency who were with and without ACD. There was no significant difference in plasma lipids, lipoproteins, and CETP between the two groups, whereas HTGL activities were significantly lower in the heterozygotes for CETP deficiency with ACD than in the heterozygotes without ACD and in control subjects. These results suggest that marked HALP may not always be a beneficial state and that people who are heterozygotes for CETP deficiency and who have low HTGL may be susceptible to ACD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Yamamura, T., Yamamoto, A., Sumiyoshi, T., Hiramori, K., Nishioeda, Y., & Nambu, S. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111532 · Cited by 91
Cited by
von Eckardstein, A., Nofer, J.-R., & Assmann, G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.1.13 · Cited by 695
Zhong, S., Sharp, D. S., Grove, J. S., Bruce, C., Yano, K., Curb, J. D., & Tall, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118751 · Cited by 583
Fayad, Z. A., Mani, V., Woodward, M., Kallend, D., Abt, M., Burgess, T., Fuster, V., Ballantyne, C. M., Stein, E. A., Tardif, J.-C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61383-4 · Cited by 538
Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL
Zannis, V. I., Chroni, A., & Krieger, M. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0030-4 · Cited by 390
HDL-targeted therapies: progress, failures and future
Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354
Metadata
- Authors
- Hirano, K.-I., Yamashita, S., Kuga, Y., Sakai, N., Nozaki, S., Kihara, S., Arai, T., Yanagi, K., Takami, S., Menju, M., Ishigami, M., Yoshida, Y., Kameda-Takemura, K., Hayashi, K., & Matsuzawa, Y.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1995-11
- Volume
- 15
- Issue
- 11
- Pages
- 1849-1856
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2130368942
- Cited by
- 178
- References
- 4
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atherosclerotic Disease in Marked Hyperalphalipoproteinemia: Combined Reduction of Cholesteryl Ester Transfer Protein and Hepatic Triglyceride Lipase. https://app.cochat.ai/papers/10.1161/01.atv.15.11.1849
- The paper
- Hirano, K.-I., Yamashita, S., Kuga, Y., Sakai, N., Nozaki, S., Kihara, S., Arai, T., Yanagi, K., Takami, S., Menju, M., Ishigami, M., Yoshida, Y., Kameda-Takemura, K., Hayashi, K., & Matsuzawa, Y. (1995). Atherosclerotic Disease in Marked Hyperalphalipoproteinemia: Combined Reduction of Cholesteryl Ester Transfer Protein and Hepatic Triglyceride Lipase. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.15.11.1849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.